A clinical-stage biotechnology company developing oral drug delivery technologies, with a focus on oral insulin and other peptide-based therapies. Its lead programs aim to replace injectable treatments with capsule formulations, targeting diabetes and additional metabolic conditions. Investors track...
2 members of Congress have disclosed 4 trades in Oramed Pharmaceuticals Inc. (ORMP), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 3 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-01-10 | Brad Knott | sell | $15K – $50K |
| 2022-01-14 | Andrew Garbarino | sell | $1K – $15K |
| 2021-10-01 | Andrew Garbarino | sell | $1K – $15K |
| 2021-04-23 | Andrew Garbarino | buy | $1K – $15K |